AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: Solu-Medrol®:5mg/kg intravenous infusion during the surgery;
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: 1. Apply Transesophageal Echocardiography（TEE）after anesthesia induction;~2. Goal-directed fluid management.
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: 1. Infusion of Human Albumin Grifol®20% 50ml;~2. Ultrafiltration(TERUMO CARDIOVASCULAR SYSTEMS (TERUMO®));~3. Shorten the Cardio-pulmonary Bypass line；~4. Continuous near infrared spectrum monitoring of cerebral oxygen saturation(MNIR-P100（chongqingmingxi®）)
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: Monitor urine volume closely, over 0.5ml/kg·h.
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: Protective ventilation strategy：Low tidal volume about 6\~8ml/kg and positive end expiratory pressure（PEEP） combined with lung recruitment maneuver
Study NCT00724737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Presurgical MRI
Description: People who are scheduled to have brain surgery with undergo a fMRI of the brain before surgery. This is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan.
Study NCT00724737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: functional MRI (fMRI) of the brain
Description: Healthy subjects will be undergo a brain fMRI of the brain. fMRI is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan.
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: 1. Bilateral thoracic paravertebral block before induction of anesthesia;~2. Fast channel anesthesia:~   * Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg; ②. Maintain use Remifentanil Hydrochloride for Injection 0.1\~0.4ug/kg·min, Propofol Injection 2\~6mg/kg·h, Sevoflurane 0.5\~1.5（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg·h,Vecuronium 0.06\~0.12mg/kg·h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over.
Study NCT04320914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity LASER Therapy
Description: The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~1. Initial phase (710 and 810 mJ/cm2 for a total of 500 J)~2. Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~3. Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J Duration of the treatment will be 8 minutes in one session/knee joint for each day for 3 days/week for 8 weeks.
Study NCT04320914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen gel phonophoresis
Description: Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. Each treatment session will last for 8 min with one session each day for 3 days/week for 8 weeks.
Study NCT04367740 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: To assess for development of IgG antibodies against SARS-CoV2
Description: Swabs will be collected to assess for COVID-19 if PPE supplies allow.
Study NCT02802488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A blood sampling will be performed in patients diagnosed with atrial fibrillation in order to test if having a D-dimers value superior or equal to the patient's age is predictive of a thrombus.~Thombus will be diagnosed according to the standard of care.
Study NCT02104349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: One hour training with mindfulness instructor. Listening to mindfulness CD twice a day for 2 weeks prior to spine surgery. Post-operative practice will be at least 1 track per day.
Study NCT00703781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromfenac ophthalmic solution
Description: sterile ophthalmic solution
Study NCT00703781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sterile ophthalmic solution
Study NCT04159025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreDx Pulmonary Mini-Forceps
Description: Manufactured by Boston Scientific
Study NCT04218305 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Level Of Fetuin A
Study NCT01428479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR121167 Solution
Description: GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg
Study NCT01428479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution will be administered intravenously.
Study NCT01579162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Description: The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days
Study NCT00494195 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV1.tMCK.human-alpha-sarcoglycan- First cohort
Description: The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml.~In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
Study NCT00494195 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort
Description: The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
Study NCT01968915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161
Description: Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.
Study NCT01968915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will receive weekly paclitaxel as intravenous infusion over 1 hour in combination with LCL161, from cycle 2 in dose escalation part or from the first cycle in dose expansion part, and will continue it until unacceptable toxicity, disease progression and/or withdrawal of consent.
Study NCT03678506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban 2.5 mg x 2 will be administered to patients with positive D-dimer results
Study NCT03709914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZTI-01 100 mg/kg
Description: ZTI-01 intravenous (IV)
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: 1. Drink water after 6h, 200ml once, 2\~3 times / day，~2. early ambulation，mobilization within 48 h,~3. Intravenous the conventional antiemetic drugs Tropisetron hydrochloride Injection 12mg qd；~4. Intravenous the lansoprazole 30mg q12h.
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional control group
Description: Routine preoperative psychological preparation for patients.
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: After operation use Ropivacaine 100mg infiltrating intercostal wound and self-controlled intravenous analgesia pump is applicable(Sufentanil 0.05ug/kg·h combine with Ketamine 40ug/kg·h).
Study NCT03709914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZTI-01 75 mg/kg
Description: ZTI-01 intravenous (IV)
Study NCT00676806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood After Myeloablative Conditioning
Description: cyclophosphamide (60mg/m2 days -6 \& -5), fludarabine (25 mg/m2 days -7, -6, \& -5) and total body irradiation (days -3, -2, \& -1, total 1200 cGy) followed by cord blood infusion on day 0.
Study NCT00676806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood After Reduced-Intensity Conditioning
Description: Extracorporeal Photopheresis (days -8 \& -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 \& -4), total body irradiation (days -3 \& -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
Study NCT02005211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293
Description: Oral solution
Study NCT02005211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution
Study NCT02576171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-therapy + ICBT
Description: The group therapy supported ICBT treatment program is a combined web-based and face-to-face intervention that will involve adolescents as well as their parents. The program is founded on and inspired by previously evaluated and evidence-based interventions. Altogether, adolescents go through 12 chapters/sessions, 3 of which are face-to-face group sessions at the research clinic, and 9 of which are web-bases chapters. The program is divided into three different phases, starting with psychoeducation regarding social anxiety and the rationale for a cognitive behavioral intervention. Phase two is the main part of treatment and contains behavioral interventions, mainly exposure and habituation to feared situations and/or stimuli.
Study NCT02545686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chest wall movement assessment without CPAP
Description: While subject is breathing normally, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
Study NCT02545686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath hold assessment without CPAP
Description: While subject is breathing normally, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
Study NCT02545686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest wall movement assessment with CPAP
Description: While subject is breathing via CPAP machine, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional control group
Description: 1. Routine bowel preparation;~2. Liquid food eating 2 days before the operation;
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional control group
Description: Intramuscular injection of scopolamine 0.3mg combined with morphine 10mg before surgery;
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional control group
Description: 1. Induction use Sufentanil 0.5\~1ug/kg, Vecuronium 0.15mg/kg and Etomidate 0.2\~0.6mg/kg,Midazolam0.05\~0.1mg/kg ;~2. Maintain use Sufentanil 1\~2ug/kg·h, Propofol 4\~12mg/kg·h, Sevoflurane 1\~3(minimal alveolar concentration)， Vecuronium 0.06\~0.12mg/kg·h;
Study NCT01691716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tendoactive
Description: Food supplement containing mucopolysaccharides, type I collagen and vitamin C
Study NCT01691716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tendoactive
Description: Food supplement containing mucopolysaccharides, type I collagen and vitamin C
Study NCT01691716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric training
Description: Eccentric training program published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
Study NCT02577939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval Exercise Training (IET)
Description: This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
Study NCT01441284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole
Description: pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily
Study NCT01441284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pramipexole
Description: pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily
Study NCT02545686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breath hold assessment with CPAP
Description: While subject is breathing via CPAP machine, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
Study NCT01441284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03675685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCH (collagenase clostridium histolyticum)
Description: A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.
Study NCT01441284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03651934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal iron
Description: The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional control group
Description: Use self-controlled intravenous analgesia pump containing Sufentanil 0.07ug/kg·h
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional control group
Description: Intravenous infusion of dexamethasone 20mg during the surgery
Study NCT03651934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weak iron
Description: The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
Study NCT03651934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal selenium
Description: The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d). The second stage lasts for 4 weeks. For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
Study NCT03651934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weak selenium
Description: The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d). The second stage lasts for 4 weeks. For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
Study NCT04310267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Petit typeface mask
Description: (Intraoral) Hyrax expander for maxilary sutures disarticulation through expansion, (Extraoral) Face mask for generating maxillary protraction forces and head gear face-bow to act as a connector between both intra and extra oral parts.
Study NCT04147637 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre with MiaoMiao
Description: Use of FreeStyle Libre with MiaoMiao Bluetooth adjunct and mobile device application to enable calibration and alarms
Study NCT04147637 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Libre alone
Description: Use of standard FreeStyle Libre with Libre Link app and mobile phone scanning
Study NCT01281436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HeartSmartKids & Web-based Provider Training
Description: The providers assigned to Group 2 will receive the web-based training described in the web-based training arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
Study NCT01943136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: papaya 1% extract ointment
Study NCT01281436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web-based Provider Training
Description: The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
Study NCT01281436 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Web-based Provider Training
Description: The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
Study NCT04464031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic alert
Description: The e-alert system was developed by the divisions of Nephrology and Information Management of Guangdong Provincial People's Hospital (Patent Application 201610001950.5). The alert system made a diagnosis of acute kidney injury according to Kidney Disease: Improving Global Outcomes criteria. Then, the doctor receives an alert of acute kidney injury.
Study NCT00808834 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon A contact lens
Description: Investigational, silicone hydrogel, spherical, soft contact lens
Study NCT00808834 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lens
Description: Commercially marketed, silicone hydrogel, spherical, soft contact lens
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional control group
Description: Intravenous infusion of flucloxacillin sodium 1g before the operation
Study NCT04424056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra +/- Ruxolitinib (stages 2b/3)
Description: administration of Anakinra +/- ruxolitinib, depending of evolution
Study NCT04424056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra and Ruxolitinib (Advanced stage 3)
Description: administration of Anakinra and ruxolitinib
Study NCT01943136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mupirocin 2% ointment
Study NCT04424056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab +/- ruxolitinib (stages 2b/3)
Description: administration of Tocilizumab +/- ruxolitinib, depending of evolution
Study NCT01212822 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01212822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV